SCHEMBL5598116

SCHEMBL5598116

Cc1oncc1C(O)CC(=O)O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.35
ALDH1A1 P00352 1/20 0.33
HSD17B10 Q99714 1/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
LMNA P02545 2/20 0.33
GMNN O75496 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
HTR1A P08908 1/20 0.33
THRB P10828 1/20 0.33
PIM1 P11309 1/20 0.33
CYP2C9 P11712 1/20 0.33
MAOA P21397 1/20 0.33
SLC6A2 P23975 1/20 0.33
HTR2A P28223 1/20 0.33
AGTR1 P30556 1/20 0.33
CCKBR P32239 1/20 0.33
MC4R P32245 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20501825 0.73 CSF1R (0.37) CSF1RALDH1A1HSD17B10NPC1RAB9A
SCHEMBL22188458 0.71 LMNA (0.39) CSF1RALDH1A1HSD17B10NPC1RAB9A
SCHEMBL3448381 0.69 CTSA (0.47) CTSA
SCHEMBL20475050 0.69 MAPT (0.33) ALDH1A1LMNATP53HTTMAPT
SCHEMBL3101768 0.66 PTPRA (0.37) CSF1RALDH1A1HSD17B10NPC1RAB9A
SCHEMBL10349460 0.66 TSHR (0.42) ALDH1A1SMN1; SMN2CTSAKDM4E
SCHEMBL279917 0.64 FFAR1 (0.51) ALDH1A1CYP2C19SMN1; SMN2CYP26A1
SCHEMBL1262878 0.64 NPSR1 (0.50) ALDH1A1LMNATP53CYP1A2CYP2C19
SCHEMBL8771313 0.63 POLB (0.57) RAB9ALMNACYP1A2HTTSMN1; SMN2
SCHEMBL30556756 0.63 AKR1B1 (0.45) ALDH1A1LMNACYP1A2HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7192931-B2 Treatment of demyelinating diseases NEUREN PHARMACEUTICALS LTD. (NZ) 2007-03-20 US claimed
WO-2025030033-A1 APILIMOD COMPOSITIONS AND METHODS OF USE ORPHAI THERAPEUTICS INC. (US) 2025-02-06 WO disclosed
CN-116930351-A Method for measuring related substances of key starting materials of pirenzepine by HPLC 上海现代制药股份有限公司 2023-10-24 CN disclosed
EP-4188382-A1 ADMINISTRATION OF MODULATORS OF 5-HT AND/OR AMPA RECEPTORS FOR TREATING NEUROLOGICAL CONDITIONS The Royal Institution for the Advancement of Learning / McGill University (CA) 2023-06-07 EP disclosed
WO-2022023813-A1 ADMINISTRATION OF MODULATORS OF 5-HT AND/OR AMPA RECEPTORS FOR TREATING NEUROLOGICAL CONDITIONS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2022-02-03 WO disclosed
US-20170312308-A1 XENON AND/OR ARGON TREATMENT AS AN ADJUNCT TO PSYCHOTHERAPY FOR PSYCHIATRIC DISORDERS THE MCLEAN HOSPITAL CORPORATION (US) 2017-11-02 US disclosed
US-9737562-B2 Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders THE MCLEAN HOSPITAL CORPORATION (US) 2017-08-22 US disclosed
US-20150306136-A1 XENON AND/OR ARGON TREATMENT AS AN ADJUNCT TO PSYCHOTHERAPY FOR PSYCHIATRIC DISORDERS THE MCLEAN HOSPITAL CORPORATION (US) 2015-10-29 US disclosed